Earnings Feed
Start Free
AbbVie Inc.·4

Feb 20, 6:35 PM ET

Stewart Jeffrey Ryan 4

4 · AbbVie Inc. · Filed Feb 20, 2026

Research Summary

AI-generated summary of this filing

Updated

AbbVie (ABBV) EVP Stewart Jeffrey Ryan Receives Awards

What Happened

  • Stewart Jeffrey Ryan, Executive Vice President & Chief Commercial Officer of AbbVie, was the recipient of awards on Feb 18, 2026 totaling 80,561 shares (recorded at $0.00). The filing shows four performance-based equity awards (26,063; 9,266; 9,432; 8,988 shares) and a derivative award/employee stock option for 26,812 shares. The performance awards were certified by the Compensation Committee and the shares will be issued on Feb 28, 2026. The option grant vests/exercises on a future schedule (see details below).

Key Details

  • Transaction date: February 18, 2026; Form 4 filed February 20, 2026 (appears timely).
  • Reported price: $0.00 for all awards (compensation grants, not open-market buys).
  • Total shares/awards: 80,561 shares (aggregate of the five reported items).
  • Issuance: Performance-based shares (per footnotes) will be issued on February 28, 2026.
  • Option (derivative): 26,812-share option becomes exercisable in annual increments of 8,938 (Feb 18, 2027), 8,937 (Feb 18, 2028) and 8,937 (Feb 18, 2029); option grant was made pursuant to AbbVie’s 2013 Incentive Stock Program and is exempt under Rule 16b-3.
  • Shares owned after transaction: not disclosed in the filing.
  • Notable footnotes: awards are performance-vesting (based on EPS, relative TSR, relative ROE) and were certified by the Compensation Committee; reporting person disclaims beneficial ownership of securities held by spouse.

Context

  • These transactions are compensation awards and performance-vesting restricted stock/RSU certifications, not open-market purchases or sales. Such awards are routine elements of executive pay and reflect achievement of pre-set performance goals; they do not by themselves indicate an insider buying or selling the company’s stock. The option grant vests in future years and is not an immediate exercise or sale.

Insider Transaction Report

Form 4
Period: 2026-02-18
AbbVie Inc.ABBV
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
Transactions
  • Award

    Common Stock, $0.01 par value

    [F1]
    2026-02-18+26,063→ 79,297 total
  • Award

    Common Stock, $0.01 par value

    [F2]
    2026-02-18+9,266→ 88,563 total
  • Award

    Common Stock, $0.01 par value

    [F3]
    2026-02-18+9,432→ 97,995 total
  • Award

    Common Stock, $0.01 par value

    [F4]
    2026-02-18+8,988→ 106,983 total
  • Award

    Option (Right to Buy)

    [F6]
    2026-02-18+26,812→ 26,812 total
    Exercise: $230.04Exp: 2036-02-17→ Common Stock (26,812 underlying)
Holdings

  • Common Stock, $0.01 par value

    [F5]
    (indirect: By Trust)
    1,338
Footnotes (6)
  • [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F5]The reporting person disclaims beneficial ownership of all securities held by his spouse.
  • [F6]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,938 on February 18, 2027, 8,937 on February 18, 2028, and 8,937 on February 18, 2029.
Signature
/s/ T.O. Odutayo, Attorney-in-Fact for Jeffrey R. Stewart|2026-02-20

Documents

1 file
  • 4
    form4-02202026_060213.xmlPrimary